No serious adverse effect monitored among vaxxed kids aged 5 to 11, says DOH | Inquirer

No serious adverse effect monitored among vaxxed kids aged 5 to 11, says DOH

By: - Reporter /
/ 02:02 PM February 17, 2022

Pediatric vaccination at the Philippine Children's Medical Center. Image from PCMC

Pediatric vaccination at the Philippine Children’s Medical Center. Image from PCMC

MANILA, Philippines — No serious adverse effects have so far been monitored since the government started its COVID-19 immunization of children aged 5 to 11 years, an official of the Department of Health (DOH) said Thursday.

Health Undersecretary Myrna Cabotaje said that as of Feb. 16, a total of 263,932 children aged 5 to 7 years across the country have already received their first dose of the Pfizer COVID-19 vaccine.

FEATURED STORIES

“Walang serious na adverse side effects pero may walong kaso tayo ng non-serious adverse events,” she said in a Laging Handa public briefing.

(We did not record any serious side effects but there are eight cases of non-serious adverse events.)

Article continues after this advertisement

Out of the eight cases, four reported experiencing sore or itchy throats. While most cases only reported rashes, Cabotaje said there are cases who reported having fever and vomiting.

Article continues after this advertisement

Only the Pfizer COVID-19 vaccine has an emergency use approval for kids aged 5 to 11 years old.

The government piloted the pediatric COVID-19 vaccination on children 5 to 11 years old on Feb. 7 in Metro Manila. It then rolled out the inoculation nationwide starting Feb. 14.

Children who received their first dose are expected to get their second dose after three weeks.

EDV
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

www
www
entertainment
business
globalnation
TAGS:

No tags found for this post.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.